KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
91.4%−3.6 pts over 5 years
Operating margin
-712.7%−603.8 pts over 5 years
Net margin
2848.6%+2956.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -78.3% | -64.2% | -48.4% | -28.4% | |
| Gross profit | -58.2% | -63.4% | -48.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -34.8% | -40.3% | -143.5% | |
| Return on assets | -12.4% | -22.5% | 109.8% | |
| Current ratio | 4.09 | 4.63 | 3.39 | |
| Interest coverage | -4.7× | -79.9× | -5.2× | |
| Inventory turnover | – | 0.8× | 0.2× | |
| Capex to revenue | 0.7% | 2.3% | 0.6% | |
| Diluted shares | 3M | 4M | 4M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kyntra Bio generated $685.96M from operations and spent $11.75M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$685.96M
Used
$11.75M
Capital expenditure$11.75M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin2848.6%
×Asset turnover0.04×
×Equity multiplier-1.31×
=Return on equity, FY2025-143.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 2848.6% | 0.04× | -1.31× | -143.5% |
| FY2024 | -160.6% | 0.09× | -1.48× | 22.1% |
| FY2023 | -607.3% | 0.09× | -4.58× | 252.0% |
| FY2022 | -208.7% | 0.20× | 7.37× | -312.9% |
| FY2021 | -123.3% | 0.29× | 2.54× | -91.9% |
| FY2020 | -107.4% | 0.21× | 1.79× | -40.3% |
| FY2019 | -30.0% | 0.30× | 1.70× | -15.0% |
| FY2018 | -40.6% | 0.24× | 1.71× | -16.7% |
| FY2017 | -92.3% | 0.19× | 2.00× | -35.3% |
| FY2016 | -31.7% | 0.39× | 2.82× | -34.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$183.45M
- Cash generatingOperating cash flow above zero-$4.77M
- Return on assets improvedROA up on the prior year-11.2% → 85.5%
- Earnings backed by cashOperating cash flow above net income-$4.77M vs $183.45M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.47 → 3.39
- No dilutionShare count did not rise4M → 4M
- Gross margin improvedGross margin up on the prior year47.47% → 91.37%
- More efficientAsset turnover rose0.07 → 0.03